Increasing evidence (11, 12) has linkedphosphodiesterase 4 (PDE4) inhibition to the therapeutic management ofrespiratory diseases, and roflumilast has been used as an oral medication inpatients with COPD with a prior history of hospitalization for an acuteexacerbation (GOLD 2021). The gene discussed is PDE4A; the disease is glycogen storage disease VI.